Clinical Trials Logo
  1. Home
  2. Adenovirus
  3. NCT06299813

Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection — Adeno-beta  

Adenovirus Clinical Trial

Official title:
A Double-blind, Placebo-controlled Randomized Study Comparing the Effectiveness of a Single Dose of Betamethasone vs Placebo in Children With Symptomatic Adenovirus Infection

Clinical Trial Summary

The goal of this double-blind, Placebo-controlled Randomized Study is to assess if a single dose of betamethasone in children with febrile adenoviral infection works well in achieving an early fever regulation. The experimentation is conducted to answer this question: "Can betamethasone help reduce fever more quickly in a child with viral adenovirus infection? "The secondary objective is to assess if the child's overall clinical conditions improve more rapidly (reduced sore throat, quicker return to regular eating) and a reduction in the incidence and duration of hospitalizations.

Clinical Trial Description

Adenovirus pharyngitis is a highly febrile illness and tends to last for up to 5-7 days if treated only with antipyretics. Currently, there are no evidence-based effective treatments for this infection. The use of single-dose betamethasone is believed to be effective in significantly reducing the hyper-inflammation that the virus can induce in pediatric patients. However, it is an empirical therapeutic practice used variably because positive clinical experience encourages its prescription but lacks experimental evidence. The main question at hand is whether the single administration of betamethasone at a dosage of 0.1 mg/kg is truly effective in symptomatic adenoviral infection and whether it can, therefore, reduce the overall fever duration and improve the clinical condition of the children. The study does not involve changes to current clinical practice but aims to demonstrate that this clinical practice, mostly used empirically, is actually based on scientific evidence. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06299813
Study type Interventional
Source A.O.U. Città della Salute e della Scienza
Contact Claudia Bondone, MD
Phone +390113131611
Email cbondone@cittadellasalute.to.it
Status Recruiting
Phase Phase 3
Start date March 20, 2024
Completion date April 1, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT02984280 - Specific Respiratory Infections as Triggers of Acute Medical Events N/A
Recruiting NCT03665675 - Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT Early Phase 1
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Recruiting NCT03266627 - Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection Phase 2
Not yet recruiting NCT03325517 - Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics N/A
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Recruiting NCT05183490 - R-MVST Cells for Treatment of Viral Infections Phase 1
Completed NCT04056546 - Interest of Rapid Typing in Adenovirus Infections.
Withdrawn NCT00448994 - Adenovirus and Fungal Load in Pediatric Stem Cell Transplant Patients N/A
Enrolling by invitation NCT06027879 - Anti-viral T-cell Therapy by Gamma Capture Phase 1/Phase 2
Recruiting NCT02779439 - Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation Phase 1
Terminated NCT02420080 - A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304 N/A
Active, not recruiting NCT01945814 - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Phase 1
Completed NCT01535885 - Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV Phase 1
Terminated NCT03339401 - The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation Phase 2
Withdrawn NCT01584037 - Adenovirus Vaccine Pregnancy Registry N/A
Withdrawn NCT03532035 - Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia Phase 2
Recruiting NCT02008812 - Ad Sensor-based Real-time Diagnosis of Adenovirus N/A
Active, not recruiting NCT04364178 - Viral Specific T-Lymphocytes to Treat Adenovirus or CMV Phase 1/Phase 2
Recruiting NCT05664126 - Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation Phase 2